NRSN NeuroSense Therapeutics Ltd. Insider Trading

CEO Alon Ben-Noon purchases 250,000 shares of NRSN via private placement at $0.80; holdings rise to 4.53M shares.

Alon Ben-Noon, Chief Executive Officer, purchased 250,000 shares at $0.80 on 2026-06-16 through a private placement, increasing his holdings from 4.28M to 4.53M shares. This transaction is a PIPE/registered direct allocation, not a discretionary open-market purchase, and therefore should not be interpreted as a conviction-driven buying signal. The stock is trading at $0.80, which is 68.2% below its 52-week high of $2.52, though it has gained 5.0% over the past 30 days. The CEO's participation in the capital raise maintains alignment with shareholders, but the structured nature of the transaction limits conclusions about internal sentiment regarding valuation or company trajectory.

CFO Or Eisenberg buys 250,000 NRSN shares at $0.80 in private placement, raising stake to 1,504,050 shares

Or Eisenberg, Chief Financial Officer, purchased 250,000 shares at $0.80 on 2026-06-16 via a private placement, not an open-market transaction. This increased his holdings from 1,254,050 to 1,504,050 shares. The stock currently trades at $0.80, which is -68.2% from its 52-week high of $2.52, though it has recovered +5.0% over the past 30 days. Because this transaction is a private placement allocation rather than a discretionary open-market purchase, it does not reflect conviction-driven buying decisions by the insider. Investors should focus on the company's underlying fundamentals and capital structure rather than inferring signal from this mandated or negotiated share acquisition.